Introduction
============

Myocardial pathologies are significant causes of morbidity and mortality in patients worldwide. Ischemic and non-ischemic cardiomyopathies have become a worldwide epidemic of the 21st century with an increasing impact on health care systems. The 2012 European Society of Cardiology and 2013 American College of Cardiology Foundation/American Heart Association guidelines provide current therapy guidance to reduce mortality and morbidity[@R1],[@R2],[@R3],[@R4]. The revascularization of coronary arteries in acute myocardial infarction has become the treatment of choice, and revascularization procedures have evolved significantly. Coronary angiography is invasive and provides information only on the anatomical status of obstructive coronary lesions. Several non-invasive methods have been developed to aid in the assessment of the functional state of the myocardium, namely contraction and perfusion, as well as microvascular and cellular integrity, including positron emission tomography and contrast, enhanced echocardiography[@R5],[@R6],[@R7],[@R8]. More recently, the development of delayed contrast-enhanced magnetic resonance imaging (DE-MRI) has served a purpose as another imaging tool. In ischemic cardiomyopathy, the sub-endocardium is always enhanced on DE-MRI, while a patchy mid-myocardial enhancement is observed in dilated cardiomyopathy (DCM). Furthermore, patients with restrictive cardiomyopathy showed delayed myocardial improvement over the entire sub-endocardial circumference[@R9],[@R10],[@R11],[@R12]. Heart failure represents the final stage in the continuum of cardiovascular diseases. Cardiac remodelling is a key component of heart failure that progresses from adaptive to maladaptive as the disorder worsens. Increased myocardial wall stress during diastole contributes to the development and progression of adverse cardiac remodeling[@R13],[@R14],[@R15]. Cardiac magnetic resonance is superior to other cardiac imaging modalities such as echocardiography, computed tomography angiography and coronary angiography in determining the type of cardiomyopathy, and cardiac function[@R16],[@R17].

Methods
=======

Patient characteristics
-----------------------

The age of participants in the included 12 cardiomyopathy studies ranged from 18 to 87 years, with dilated cardiomyopathy being a more seen pathology in the studies followed by ischemic cardiomyopathy. The patient characteristics are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of patients

  Category                                     
  -------------------------------------------- ---------
  Sample size information                      
  Total number of patients included            999
  Number of studies reporting on sample size   12
  Range of sample size reported                23--150
  Age of participants                          
  Number of studies reporting on age           10
  Age range, yrs                               18--87
  Type of cardiomyopathy                       
  Ischemic cardiomyopathy                      193
  Dilated cardiomyopathy                       337
  Dual pathologies (NICM and DCM)              16
  Hypertrophic cardiomyopathy                  70
  Tachycardia-induced cardiomyopathy           55
  Myocarditis                                  138
  Cardiac amyloidosis                          119
  Cardiac sarcoidosis                          14
  Left ventricle non-compaction                57
  Other tests                                  
  Histopathology                               1
  Echocardiography                             2
  Coronary angiography                         1

Abbreviations: NICM= nonischemic cardiomyopathy, DCM= dilated cardiomyopathy

Identification of studies and journals
--------------------------------------

We identified published studies using CMR in the diagnosis of different types of cardiomyopathy in original and review articles by systematic searches of PubMed, MedLine, Cochrane database and Embase, and by manual searches of listed references in the papers, we found. We limited our search to studies published from January 2013 to April 2017 because, during this period, we noted an increase in the application of CMR in diagnosing different types of cardiomyopathy. The keywords used were: "dilated cardiomyopathy", "ischemic cardiomyopathy", "hypertrophic cardiomyopathy", "myocarditis", "cardiac amyloidosis", "cardiac sarcoidosis", and "cardiac MR", or "LGE CMR" (late gadolinium enhancement cardiovascular magnetic resonance), "Cine CMR", and "sensitivity" or "specificity". We identified 62 studies through this search strategy. We further screened the reference list of the retrieved studies for any additional publications. There were no restrictions on studies based on their sample size.

Eligibility criteria
--------------------

We considered all eligible studies that evaluated the role of CMR in the diagnosis of cardiomyopathy. We also included studies with sufficient information to allow the calculation of sensitivity and specificity. We excluded meeting reports, abstracts, and reviews whose final stories were unavailable.

Data extraction
---------------

For each eligible study, we extracted the following information: author names, journal, year of publication, number of enrolled patients, the age of study patients, study design, and CMR protocol.

Statistical analysis
--------------------

Statistical analysis was done using MedCalc for Windows version 64 bits; we calculated the sensitivity, specificity, positive predictive value, negative predictive value, positive likely-hood ratio, and negative likelihood ratio.

Results
=======

Eligible studies
----------------

The search yielded 35 relevant studies. Of these, due to limited data, 23 studies were excluded, and 12 studies were available for systematic review. [Figure 1](#F1){ref-type="fig"} summarizes the flow diagram of how eligible studies were obtained. These studies were selected because they related to our analysis, they were recent, and they had likely extractable data as shown in [figure 1](#F1){ref-type="fig"}.

![The flow diagram of study selection process for systematic review](MMJ3004-0291Fig1){#F1}

Study description and patient characteristics
---------------------------------------------

The 12 studies had a total of 999 patients. The sample size of the studies ranged from 23 to 150. The age range of the study subjects, 18 to 87 years, was reported in 10 reviews. Dilated cardiomyopathy was more prevalent in the studies, followed by ischemic cardiomyopathy and the least pervasive was cardiac sarcoidosis. The average sensitivity and specificity of CMR in the diagnosis of cardiomyopathy was 86.75% (95% confidence interval \[CI\], 70.30% to 92.58%) and 81.75% (95% CI, 73.0% to 87.6%), respectively. The positive predictive and negative predictive values were 80.17% and 86.75%. [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, and [4](#T4){ref-type="table"} summarize the results.

###### 

individual studies with sample sizes and types of cardiomyopathy

  ----------------------------------------------------------------------------------------------------
  Study                    Sample\   CMR           Findings
                           size                    
  ------------------------ --------- ------------- ---------------------------------------------------
  Goebel et al.[@R18]\     150       T1 mapping\   Does not differentiate healthy and diffusely\
  2016                               CMR           diseased myocardium

  Makoto et al.[@R19]\     44        LGE CMR       LE in CS predominantly basal, mid septum\
  2016                                             and throughout the LV, while in DCM, LE was\
                                                   localized in the basal and mid septum

  Mikami et al.[@R20]\     118       LGE CMR       Septal fibrosis
  2016                                             

  Okada et al.[@R21]\      102       LGE CMR       TIC had a significant lower RVEF, and a\
  2016                                             larger RVEDV and RVEDS

  Kwong et al.[@R22]\      81        Cine SSFP\    CA mean proportion of atrial enhancement\
  2015                               and LGE       was significantly greater compared to SH and\
                                                   NIDCM

  Maurizio et al.[@R23]\   77        LGE CMR       Hypertrophied septum indicating regional\
  2015                                             fibrosis in HCM

  Schwab et al.[@R24]\     43        CMR           Wall motion abnormalities
  2015                                             

  Nguyen et al.[@R25]\     23        CMR/LGE\      Diffuse myocardial fibrosis
  2015                               CMR           

  Dungu et al.[@R26]\      97        LGE CMR       Distinguished ATTR from AL cardiac\
  2013                                             amyloidosis

  Ferreira et al.[@R27]\   50        T1 mapping\   T1 mapping is a criterion for detection of\
  2013                               CMR           acute myocarditis with a higher sensitivity

  Choi et al.[@R28]\       114       Cine CMR/\    Classification of distribution of trabeculation,\
  2016                               LGE CMR       43.9% global type, 56.2% apical type

  Gulsin et al.[@R29]\     100       CineCMR/\     Global LV hypokinesis
  2017                               LGE CMR       
  ----------------------------------------------------------------------------------------------------

Abbreviations: CMR= cardiac magnetic resonance, LGE= late gadolinium enhancement, LE= late enhancement, CS= cardiac sarcoidosis, DCM= dilated cardiomyopathy, TIC= tachycardia induced cardiomyopathy, RVEDV= right ventricle end diastolic volume, RVEDS= right ventricle end systolic volume, CA= cardiac amyloidosis, SH= systemic hypertension, NIDCM= Nonischemic dilated cardiomyopathy, HCM= hypertrophic cardiomyopathy, AL= amyloid light chain, ATTR= transthyretin related Amyloidosis, SSFP= steady state free precision

###### 

Showing individual studies with sensitivity, specificity and confidence intervals

  Study                        Sensitivity   95% CI       Specificity   95% CI       FPR(1-TPR)
  ---------------------------- ------------- ------------ ------------- ------------ ------------
  Goebel et al.[@R18] 2016     0.85          0.75--0.91   0.75          0.66--0.83   0.15
  Makoto et al.[@R19] 2016     0.68          0.57--0.78   0.63          0.53--0.72   0.32
  Mikami et al.[@R20] 2016     0.70          0.60--0.79   0.71          0.61--0.80   0.30
  Okada et al.[@R21] 2016      0.88          0.79--0.95   0.75          0.66--0.82   0.12
  Kwong et al.[@R22] 2015      0.93          0.85--0.97   0.80          0.71--0.87   0.07
  Maurizio et al.[@R23] 2015   0.99          0.93--1.00   0.83          0.75--0.89   0.01
  Schwab et al.[@R24] 2015     0.86          0.72--0.95   1.0           0.90--1.0    0.14
  Nguyen et al.[@R25] 2015     0.84          0.75--0.95   0.80          0.72--0.88   0.16
  Dungu et al.[@R26] 2013      0.96          0.89--0.99   0.88          0.80--0.93   0.04
  Ferreira et al.[@R27] 2013   0.91          0.83--0.96   0.90          0.82--0.95   0.09
  Choi et al.[@R28] 2016       0.85          0.76--0.92   0.76          0.64--0.83   0.15
  Gulsin et al.[@R29] 2017     0.96          0.90--0.99   1.00          0.96--1.0    0.04

Abbreviations: CI= confidence interval, FPR= false positive rate, TPR= true positive rate

###### 

Showing individual studies with positive predictive value and negative predictive value

  Study                        PPV    NPV
  ---------------------------- ------ ------
  Goebel et al.[@R18] 2016     0.71   0.87
  Makoto et al.[@R19] 2016     0.57   0.73
  Mikami et al.[@R20] 2016     0.72   0.69
  Okada et al.[@R21] 2016      0.69   0.91
  Kwong et al.[@R22] 2015      0.76   0.94
  Maurizio et al.[@R23] 2015   0.80   0.99
  Schwab et al.[@R24] 2015     1.00   0.85
  Nguyen et al.[@R25] 2015     0.81   0.85
  Dungu et al.[@R26] 2013      0.87   0.96
  Ferreira et al.[@R27] 2013   0.97   0.90
  Choi et al.[@R28] 2016       0.72   0.88
  Gulsin et al.[@R29] 2017     1.00   0.96

Abbreviations: PPV= positive predictive value, NPV= negative predictive value

Discussion
==========

Cardiomyopathy has been diagnosed and assessed by echocardiogram or cardiac computed tomography for many years. With technological advancements and further research, several studies have addressed the role of cardiac magnetic resonance (CMR) as a functional modality in the diagnosis and quantification of cardiac function in different types of cardiomyopathy. CMR can measure and quantify chamber sizes and left ventricle (LV) systolic function accurately. Therefore, Cardiac Magnetic Resonance has potential as a tool to assess patient prognosis.

In our systematic review of 12 studies, we found moderately high sensitivity and specificity values for CMR, which implies that CMR is a standard valuable imaging modality for diagnosing different types of cardiomyopathy. Goebel *et al.* could differentiate between dilated cardiomyopathy, hypertrophic cardiomyopathy (HCM), and healthy heart function through left ventricle quantification; patients with dilated cardiomyopathy had higher left ventricle end-diastolic volume, end-systolic volume, and systolic volume and significantly lower ejection fractions compared to patients with healthy hearts[@R18]. Hypertrophic cardiomyopathy patients had substantially higher end-diastolic septum thickness compared to healthy subjects[@R18]. This reinforces the importance of cardiac magnetic resonance in diagnosing cardiomyopathy. CMR can also be useful in differentiating ischemic and non-ischemic cardiomyopathy, which might facilitate optimal management of patients.

According to this study, we appreciate the ability of CMR to diagnose and differentiate types of cardiomyopathies, through its high spatial resolution and tomographic image capabilities. Late gadolinium magnetic resonance was able to distinguish cardiac sarcoidosis and dilated cardiomyopathy[@R19]. Furthermore, Late Gadolinium Enhancement cardiac magnetic resonance was also used to diagnose non-ischemic Dilated cardiomyopathy by revealing septal fibrosis and other studies identified a mid-wall septal striae pattern of Late gadolinium enhancement to be the most reliable predictor of future events[@R20]. Moreover, CMR was also used to assess the diagnostic value of early right ventricular dysfunction to predict tachycardia-induced cardiomyopathy, in which the studies revealed that CMR imaging assessing right ventricular function might be valuable compared with echocardiography[@R21].

Ischemic cardiomyopathy can easily be missed in routine screening of suspected coronary heart disease patients particularly in microvascular coronary artery disease whereby coronary angiogram may be the standard investigation expected to be done. But with the current new technology of Positron emission magnetic resonance imaging (PETMRI), it will be easy to know which areas are poorly perfused and confirmed by measuring coronary flow reserve[@R30]. Among other non-invasive imaging modalities, CMR is emerging as a highly sensitive and specific test for myocardial ischemia and infarction. Resting perfusion in CMR is used to evaluate microvascular obstruction, which is shown to predict adverse left ventricular remodelling[@R31]. Thus, as previous studies have indicated, the significance of magnetic resonance in diagnosing different types of cardiomyopathies especially in differentiating ischemic versus nonischemic cardiomyopathy, we concur with our results of MRI having high sensitivity and specificity.

Clinical implications
---------------------

CMR is superior in evaluating cardiac function, LV dimensions, and capable of differentiating types of cardiomyopathies with a specificity of 81.75% and sensitivity of 86.75%. In the clinical setting, the ability to diagnose the form of cardiomyopathy helps in choosing the specific treatment. In a study of Choi *et a*l.,[@R28] they used cardiac magnetic resonance imaging to establish refined diagnostic criteria for left ventricle non-compaction. As a quantitative approach, we have shown that a trabeculated left ventricle volume of \>35% of the LV myocardial volume is diagnostic for left ventricle non-compaction with high specificity. Our study has also shown the diagnostic accuracy of late gadolinium-enhanced cardiac magnetic resonance for establishing the etiology of heart failure. Late gadolinium enhancement-cardiac magnetic resonance (LGE-CMR) was able to differentiate between ischemic cardiomyopathy and non-ischemic cardiomyopathy. Furthermore, the addition of adenosine stress perfusion-cardiac magnetic resonance (SP-CMR) to cine and LGE-CMR provided minimal incremental diagnostic yield for determining the etiology of heart failure in patients with severe left ventricle systolic dysfunction[@R29].

Limitations
===========

The inclusion of studies with small sample sizes may influence the statistical power of the individual research and lead to imprecise and inconclusive results. Other limitations include bias through selection, publication, and verification of the studies.

Conclusion
==========

Despite some limitations, our study shows that cardiac magnetic resonance (CMR) has high sensitivity, specificity, and positive predictive value in diagnosing different types of cardiomyopathy. CMR may be used to differentiate types of cardiomyopathy, accurately quantify the chamber dimensions, volumes, and cardiac function which make it useful for prognosis as well.
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